Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

In a breakthrough for cancer research, Medgnosis has leveraged its state-of-the-art generative AI (GenAI) system to transform drug discovery. This GenAI targets both druggable and undruggable proteins ...

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.

Thomas Fuchs will lead artificial intelligence initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.